# BCG033

Source: https://onco.cc/drugs/bcg033/  
OnCo record `bcg033` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BCG033 is an experimental drug designed to carry chemotherapy to cancer cells. Its published evidence is from laboratory and animal studies.

## Summary

AACR 2024 abstract 2616 describes BCG033 targeting PTK7 and TROP2. A vcMMAE construct with DAR 4 was tested in breast and lung xenografts; a separate BLD1102 TOP1 inhibitor construct with DAR 8 was tested in colorectal xenografts. These are distinct constructs, not a demonstrated dual-payload ADC. The cited results are preclinical and do not establish patient benefit.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-10-06
- Tags: evidence:preclinical
- Modality: ADC
- Mechanism: Bispecific PTK7/TROP2 antibody-drug conjugate, tested with different single-payload conjugates rather than two payloads in one molecule.
- Payload: Separate tested constructs: vcMMAE (DAR 4) or TOP1 inhibitor BLD1102 (DAR 8)

## Sources

- Publisher abstract: https://doi.org/10.1158/1538-7445.am2024-2616

## Connected records

- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Bispecific ADC](https://onco.cc/technologies/bispecific-adc/)
- targets: [PTK7](https://onco.cc/targets/ptk7/), [TROP2](https://onco.cc/targets/trop2/)

---
JSON: https://onco.cc/api/v1/entities/bcg033.json